Designated Drug Use Investigation (Long-Term Administration) of Zetia [ezetimibe] 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Trial Profile

Designated Drug Use Investigation (Long-Term Administration) of Zetia [ezetimibe] 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Antihyperlipidaemics
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II; Sitosterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2009 Planned end date changed from 1 Jun 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top